Importer of Controlled Substances Application: Lipomed/LGC Standards

The Drug Enforcement Administration (DEA) has published a notice that Lipomed/LGC Standards, located at 150 Cambridgepark Drive, Suite 705, Cambridge, Massachusetts 02140-2300, applied on February 11, 2026, to become a registered importer of numerous basic classes of controlled substances, primarily Schedule I drugs with some Schedule II. The list includes synthetic cathinones like 3-FMC (1233), mephedrone (1248), novel benzodiazepines such as etizolam (2780) and flualprazolam (2785), synthetic cannabinoids like JWH-018 (7118) and ADB-FUBINACA (7010), hallucinogens including LSD (7315) and various 2C-series compounds, opioids like heroin (9200) and multiple fentanyl analogs (9811-9850), and others like GHB (2010). This application is made under 21 CFR 1301.34(a), allowing registered bulk manufacturers and other applicants to submit electronic comments or objections via https://www.regulations.gov, or request a hearing in writing, by May 4, 2026. Comments receive a tracking number upon submission, but are not immediately public. Hearing requests must be sent to three specific DEA addresses: Hearing Clerk/OALJ, DEA Federal Register Representative/DPW, and the Administrator, all at 8701 Morrissette Drive, Springfield, Virginia 22152. The notice spans pages 16970-16974 in the Federal Register and details over 200 drug codes, focusing on high-risk Schedule I substances often associated with illicit markets, though the applicant seeks legitimate research or analytical standards import. No decision on registration has been made; this is solely a public notice for input before potential approval.

AI-generated summary. May contain errors. Refer to official sources for legal decisions.